Search Results

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective...

Erin Ellis, M.D. and Henry Kaplan, M.D.
Swedish Cancer Institute

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating...

Gary Goodman, MD
Swedish Cancer Institute

CP MGAH22 04 Phase 3 Margetuximab versus Trastuzumab

The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and...

Erin Ellis, MD
Swedish Cancer Institute

monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant or chemotherapy in women...

Erin Ellis, MD
Swedish Cancer Institute

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer

The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative...

Henry Kaplan, MD
Swedish Cancer Institute

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with...

Gary Goodman, M.D.
Swedish Cancer Institute

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate,...

Gary Goodman, M.D.
Swedish Cancer Institute

Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

The purpose of this study is to assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on both central nervous...

Tanya Wahl, MD
Swedish Cancer Institute

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody TSR-042 in...

Joshua Press, MD

Swedish Cancer Institute

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15